Horphag Research Positions Pycnogenol as Multifunctional Core Ingredient for Women's Health Formulations

For formulators and product developers navigating an increasingly crowded women's health supplement market, Horphag Research is advancing Pycnogenol® French maritime pine bark extract as a single-ingredient solution spanning skin, circulation, menopause support, and joint mobility. The positioning responds directly to documented consumer fatigue: a recent report cited by the company found that 72% of consumers feel overwhelmed by the volume of new product launches.

Pycnogenol® is a standardized blend of procyanidins, bioflavonoids, and phenolic acids sourced from French maritime pine bark. Its clinical dossier now encompasses over 160 studies involving more than 13,000 participants, supporting claims across antioxidant activity, endothelial function, microcirculation, and connective tissue integrity. That breadth of evidence distinguishes it from single isolated compounds and gives formulators a defensible multi-claim platform within a single raw material.

The menopause indication carries the most robust dataset among the women's health applications. Twenty-nine clinical studies encompassing 2,370 women have examined Pycnogenol® across life stages, with a randomized, double-blind, placebo-controlled six-month trial in 155 peri-menopausal women reporting significant improvement in headaches, hot flashes, sleep disruption, vaginal dryness, and cardiovascular concerns versus placebo, without measurable effects on hormonal levels. For regulatory affairs leads, the non-hormonal mechanism is a material distinction when evaluating label claims and applicable guidance.

Skin-health data adds a second claim pillar. A placebo-controlled three-month study in outdoor workers reported a 13% improvement in skin elasticity and a 14% reduction in seasonal moisture loss during summer months following Pycnogenol® intake. The proposed mechanism involves stimulation of collagen and hyaluronic acid synthesis, alongside inhibition of pigment overproduction linked to melasma.

Vascular and joint data round out the multi-benefit profile. Multiple randomized controlled trials document improvements in flow-mediated dilation and reductions in oxidative stress markers. In osteoarthritis research, polyphenols from Pycnogenol® were shown to distribute into synovial fluid, with inhibition of COX-2 and 5-LOX inflammatory mediators providing a mechanistic rationale for joint comfort claims.

For QA and regulatory leads evaluating ingredient sourcing, the standardized botanical specification and the depth of the clinical file are the primary due-diligence checkpoints before any multi-claim product enters the validation pipeline.

Source: Horphag Research via GlobeNewswire, 16 June 2026.